Sriram Venkataraman | CSO
Foundery Innovations

Sriram Venkataraman, CSO, Foundery Innovations

Dr. Venkataraman Sriram (Sriram) is the Chief Scientific Officer at Foundery Innovations, Inc. Sriram has over 15 years of biopharmaceutical research experience developing biological and small molecule therapeutics against immunotherapy targets. Prior to starting Foundery, Sriram was at Pionyr Immunotherapeutics from the early stages. Before getting bit by the start-up bug, Sriram was at Gilead Sciences for close to three years. Sriram established and successively led several immuno-oncology programs at Gilead Sciences and previously at Merck. At Merck Research Laboratories (formerly the Schering-Plough Biopharma prior to its acquisition by Merck), Sriram also served as the cross-site pharmacology lead for all immuno-oncology programs, including the anti-PD-1 antibody Keytruda. Sriram received his Ph.D. degree in Biochemistry and Immunology from the University of Madras, India, and completed his post-doctoral training in immunology at the Indiana University School of Medicine.


WVIC/WAC Day 1 - Nov 29 @ 13:50

Panel: Understanding the TME; what’s left to learn?

  • How can we apply proteomics to the TME – how is this informing multiple targets?
  • Balancing power of profiling and proteomics – will proteomics ever be ready for plug and play in the clinic?
  • Advances in imaging the TME
  • Characterizing effective T cell responses in and that track to the TME
  • Non-tumor components of the TME as a therapeutic strategy -stromal cells, myeloid cells, other tissue resident cells
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall